{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.3","upperLimit":"27.5","value":"19.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"}],"units":"Participants"}],"description":"ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Abemaciclib"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)","title":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}